Opioid response in paediatric cancer patients and the Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene: an Italian study on 87 cancer children and a systematic review
Authors:
- Ersilia LucenteforteELErsilia Lucenteforte
- Alfredo VannacciAlfredo Vannacci
- Giada CrescioliGiada Crescioli
- Niccolò LombardiNiccolò Lombardi
- Laura VagnoliLVLaura Vagnoli
- Laura GiuntiLGLaura Giunti
- Valentina CeticaVCValentina Cetica
- Maria Luisa ConiglioMaria Luisa Coniglio
- Alessandra PugiAPAlessandra Pugi
- Roberto BonaiutiRBRoberto Bonaiuti
- Maurizio AricòMaurizio Aricò
- Sabrina GiglioSGSabrina Giglio
Open Access
- 31 January 2019
- journal article
- review article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-14
Abstract
Genetic polymorphisms in genes involved in pain modulation have been reported to be associated to opioid efficacy and safety in different clinical settings. The association between COMT Val158Met polymorphism (rs4680) and the inter-individual differences in the response to opioid analgesic therapy was investigated in a cohort of 87 Italian paediatric patients receiving opioids for cancer pain (STOP Pain study). Furthermore, a systematic review of the association between opioid response in cancer patients and the COMT polymorphism was performed in accordance with the Cochrane Handbook and the Prisma Statement. In the 87 paediatric patients, pain intensity (total time needed to reach the lowest possible level) was significantly higher for G/G than A/G and A/A carriers (p-value = 0.042). In the 60 patients treated only with morphine, the mean of total dose to reach the same pain intensity was significantly higher for G/G than A/G and A/A carriers (p-value = 0.010). Systematic review identified five studies on adults, reporting that opioid dose (mg after 24 h of treatment from the first pain measurement) was higher for G/G compared to A/G and A/A carriers. Present research suggests that the A allele in COMT polymorphism could be a marker of opioid sensitivity in paediatric cancer patients (STOP Pain), as well as in adults (Systematic Review), indicating that the polymorphism impact could be not age-dependent in the cancer pain context. Registration number: CRD42017057831 .Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (MFAG 10465)
This publication has 42 references indexed in Scilit:
- A functional polymorphism in the catechol‐O‐methyltransferase gene is associated with osteoarthritis‐related painArthritis & Rheumatism, 2009
- Genetic variation and response to morphine in cancer patientsCancer, 2008
- Genetic Variation in the Catechol-O-Methyltransferase (COMT) Gene and Morphine Requirements in Cancer Patients with PainMolecular Pain, 2008
- Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT genePain, 2007
- COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: Evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expressionNeuroImage, 2005
- Clinical response to morphine in cancer patients and genetic variation in candidate genesThe Pharmacogenomics Journal, 2005
- The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patientsPain, 2005
- Genetic basis for individual variations in pain perception and the development of a chronic pain conditionHuman Molecular Genetics, 2004
- COMT
val
158
met
Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain StressorScience, 2003
- Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer painThe Journal of Pediatrics, 1999